MDT

Medtronic
NYSE

Real-time Quotes | Nasdaq Last Sale

102.40
-0.19
-0.19%
Opening 15:33 10/29 EDT
OPEN
102.59
PREV CLOSE
102.59
HIGH
103.05
LOW
100.89
VOLUME
2.89M
TURNOVER
--
52 WEEK HIGH
122.15
52 WEEK LOW
72.13
MARKET CAP
137.64B
P/E (TTM)
31.59
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Medtronic Nabs FDA Approval For Nerve Monitoring System
Medtronic plc (MDT) has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital nerve monitoring system, which enables physicians to identify, confirm, and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery.According to MDT, the NIM Vital system uses proprietary technology to provide detailed intraoperative nerve condition data that informs surgical strategy, increases operative efficiency and precision, and helps protect patients’ quality of life.The company also announced that it has further ramped up its ear nose and throat (ENT) portfolio with the recent acquisition of privately-held Ai Biomed Corp., maker of the PTeye parathyroid detection system. The probe-based system is designed to help confirm parathyroid tissue identified visually by the physician during thyroid surgery.“The addition of these two technologies builds on our 20-year legacy of providing innovative solutions that assist surgeons during critical head and neck procedures,” said Vince Racano, VP of Medtronic’s ENT business.“By offering these complementary technologies – the NIM Vital system to protect crucial nerves and the PTeye system to help confirm parathyroid tissue identified visually by the surgeon – we’re helping physicians address two of the most common challenges during these procedures.”The acquisition of Ai Biomed Corp. is the seventh in a series of tuck-in acquisitions that Medtronic has made in 2020. MDT states that the revenue and earnings contribution is expected to be immaterial to the Medtronic ENT business in the first year and accretive thereafter.Shares in the medical device stock are down 10% year-to-date, but the stock scores a bullish Strong Buy consensus from the Street. That’s with 18 recent buy ratings, vs 3 hold ratings and 1 sell rating.Meanwhile the average analyst price target of $120 indicates 17% upside potential from current levels.“Between delays in the development of its robotic system or the stumbles in Diabetes, MDT will still need to prove that it can be a consistent 5% grower, but with MDT’s markets growing at 5% roughly, M&A should provide a cushion to the top-line” comments BTIG analyst Ryan Zimmerman.He reiterated his buy rating on MDT with a $119 price target arguing that: “Investors should not expect incrementally more return to the bottom line as the focus will be top-line growth reinvestment, but in a market where top-line growth is highly rewarded, we think this strategy makes sense.” (See MDT stock analysis on TipRanks).Related News: Gilead Cuts 2020 Guidance As Remdesivir Sales Disappoint Eli Lilly Ends Covid-19 Trial In Hospitalized Patients On Disappointing Data Dexcom Drops 9% As Revenue Beat Fails To Impress Investors More recent articles from Smarter Analyst: * LVMH Agrees To Buy Tiffany At Lower Price; Street Sticks To Hold * Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% * Etsy Beats Q3 Estimates On Robust Online Demand * Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy
SmarterAnalyst · 6h ago
FDA clears Medtronic next-gen nerve monitoring system
The FDA grants 510(k) clearance to Medtronic's (MDT) NIM Vital nerve monitoring system which helps physicians to identify, confirm and monitor nerve function in order to reduce the risk of
Seekingalpha · 8h ago
Medtronic Expands ENT Portfolio with FDA Clearance of NIM Vital™ Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital™ nerve monitoring system, which enables physicians to identify, confirm, and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery.1 The NIM Vital system uses proprietary technology to provide detailed intraoperative nerve condition data that informs surgical strategy,2 increases operative efficiency and precision,3 and helps protect patients' quality of life.4
PR Newswire · 8h ago
University of British Columbia's energy-efficiency initiative receives a boost through the Low Carbon Economy Fund
VANCOUVER, BC, Oct. 27, 2020 /CNW/ - Canadians from coast to coast to coast are taking action to tackle climate change in their communities.
CNW Group · 1d ago
Needham picks spine technology positives from expert check-in
A Needham expert call on spine technologies has some positive read-throughs for some of its medical technology coverage, with implications for procedure volume and devices. The firm discussed spinal implants,
Seekingalpha · 2d ago
Medtronic's Abre venous stent receives FDA approval
Medtronic ([[MDT]] -2.5%) has received U.S. FDA approval for the Abre™ venous self-expanding stent system.This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow
Seekingalpha · 3d ago
Medtronic Venous Stent Receives U.S. FDA Approval To Treat Venous Outflow Obstruction
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction DUBLIN, Oct. 26, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today
Benzinga · 3d ago
West Pharmaceutical ESG Rating Upgraded; WST Stock Hits Record Highs
Investor's Business Daily · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDT. Analyze the recent business situations of Medtronic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDT stock price target is 118.79 with a high estimate of 138.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 2.13K
Institutional Holdings: 1.15B
% Owned: 85.86%
Shares Outstanding: 1.34B
TypeInstitutionsShares
Increased
645
47.20M
New
213
6.62M
Decreased
528
56.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.28%
Healthcare Equipment & Supplies
+0.23%
Key Executives
Chairman/Executive Director
Omar Ishrak
President/Chief Executive Officer/Director
Geoffrey Martha
Chief Financial Officer/Executive Vice President
Karen Parkhill
Chief Human Resource Officer/Senior Vice President
Carol Surface
Executive Vice President
Michael Coyle
Executive Vice President
Robert ten Hoedt
Executive Vice President
John Liddicoat
Executive Vice President
Sean Salmon
Executive Vice President
Brett Wall
Executive Vice President
Robert White
Senior Vice President/Chief Scientific Officer
Richard Kuntz
Senior Vice President/General Counsel/Secretary
Bradley Lerman
Independent Director
Richard Anderson
Independent Director
Craig Arnold
Independent Director
Scott Donnelly
Independent Director
Andrea Goldsmith
Independent Director
Randall Hogan
Independent Director
Michael Leavitt
Independent Director
James Lenehan
Independent Director
Kevin Lofton
Independent Director
Elizabeth Nabel
Independent Director
Denise O'Leary
Independent Director
Kendall Powell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
08/21/2020
Dividend USD 0.58
09/24/2020
05/20/2020
Dividend USD 0.58
06/25/2020
03/06/2020
Dividend USD 0.54
03/26/2020
12/06/2019
Dividend USD 0.54
12/26/2019
08/23/2019
Dividend USD 0.54
09/26/2019
06/21/2019
Dividend USD 0.54
07/05/2019
03/08/2019
Dividend USD 0.5
03/21/2019
12/07/2018
Dividend USD 0.5
12/27/2018
08/24/2018
Dividend USD 0.5
09/27/2018
06/22/2018
Dividend USD 0.5
07/05/2018
03/09/2018
Dividend USD 0.46
03/22/2018
12/08/2017
Dividend USD 0.46
12/28/2017
08/25/2017
Dividend USD 0.46
09/28/2017
06/23/2017
Dividend USD 0.46
07/05/2017
03/10/2017
Dividend USD 0.43
03/22/2017
12/09/2016
Dividend USD 0.43
12/21/2016
08/22/2016
Dividend USD 0.43
09/27/2016
06/24/2016
Dividend USD 0.43
07/06/2016
02/19/2016
Dividend USD 0.38
03/22/2016
12/11/2015
Dividend USD 0.38
12/22/2015
08/21/2015
Dividend USD 0.38
09/23/2015
06/19/2015
Dividend USD 0.38
06/25/2015
02/13/2015
Dividend USD 0.305
03/26/2015
12/04/2014
Dividend USD 0.305
12/30/2014
08/22/2014
Dividend USD 0.305
10/01/2014
06/16/2014
Dividend USD 0.305
07/01/2014
02/14/2014
Dividend USD 0.28
04/02/2014
12/06/2013
Dividend USD 0.28
12/31/2013
08/23/2013
Dividend USD 0.28
10/02/2013
06/21/2013
Dividend USD 0.28
07/02/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MDT
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Medtronic PLC stock information, including NYSE:MDT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDT stock methods without spending real money on the virtual paper trading platform.